| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
25020 |
| Drug |
Belzutifan |
| Brand |
Welireg® |
| Indication |
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable. |
| Rapid review commissioned |
06/03/2025 |
| Rapid review completed |
31/03/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of belzutifan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/04/2025 |
| Pre-submission consultation with Applicant |
28/05/2025 |
| Full submission received from Applicant |
13/11/2025 |
